Antiangiogenic therapy in oncology: current status and future directions.
about
Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesisIncidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patientsOutcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.WISP-1 positively regulates angiogenesis by controlling VEGF-A expression in human osteosarcomaPrimary and acquired resistance to biologic therapies in gastrointestinal cancers.Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.Looking for the Word "Angiogenesis" in the History of Health Sciences: From Ancient Times to the First Decades of the Twentieth Century.A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis.Cellular effects induced by 17-β-estradiol to reduce the survival of renal cell carcinoma cells.Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer.Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment.Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II studyAnti-VEGFR2 driven nuclear translocation of VEGFR2 and acquired malignant hallmarks are mutation dependent in glioblastoma.Aggretin Venom Polypeptide as a Novel Anti-angiogenesis Agent by Targeting Integrin alpha2beta1.The Pleiotropic Role of L1CAM in Tumor VasculatureCerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment.Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker.Development of a 3D angiogenesis model to study tumour - endothelial cell interactions and the effects of anti-angiogenic drugs.A controlled release system for simultaneous delivery of three human perivascular stem cell-derived factors for tissue repair and regeneration.A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.Dysregulation of TTP and HuR plays an important role in cancers.Modulation of VEGF receptor 2 signaling by protein phosphatases.New Directions in Anti-Angiogenic Therapy for Glioblastoma.Vessel pruning or healing: endothelial metabolism as a novel target?The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Ramucirumab in the treatment of non-small cell lung cancer.Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations.Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.Angiogenesis inhibitors in tackling recurrent glioblastoma.Sindbis Virus-Pseudotyped Lentiviral Vectors Carrying VEGFR2-Specific Nanobody for Potential Transductional Targeting of Tumor Vasculature.The potential role of nintedanib in treating colorectal cancer.Tumor angiogenesis and vascular normalization: alternative therapeutic targets.Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.
P2860
Q26740812-A1EBB119-80B3-4886-B689-0931AEF92A57Q28079328-F9FE1C6B-426D-4C65-8800-489654674CE0Q33441574-D53A0BF3-5361-4B51-B669-5F841E499325Q33815842-C4D99D3D-0C33-47E6-AF56-BC4F804F3B46Q33895573-231A7B6C-5FB2-467C-9061-DC84F7FDD63FQ33913901-CEB2040A-B6F7-4221-BAF4-89B5108A15C9Q36095216-4A60233E-0AC4-4DB7-92B6-D5B10B6BD0C5Q36279494-C8DB5E59-054C-4F80-BA96-C14EE0155D22Q37157371-94E55FFF-1659-45E7-AE6A-150C0E30DBEDQ37294496-664026F8-8B9D-4C46-9056-18094B5A7960Q37407384-0598B3B2-0729-48F8-B90F-4AFC189C8BE3Q37411781-39647BD1-769F-4D05-81BA-25416D927E8BQ37442586-E8318124-5A95-4C55-A15D-368F38C3DB20Q37461422-C612318D-DEBD-4447-8D37-D16826C8EB39Q37516448-F8A18EC5-51F3-44B7-B9FC-2860C5B600A4Q37593796-A7B57A13-5C22-4037-9250-58ED2C08D568Q37613594-1793CA46-607B-4F4C-BDCD-4665EA5D3966Q37677081-9149FD19-0FDA-4EB2-B1A4-099BEA8EDE38Q37690651-9C10A2E2-1071-4420-9BB0-6D850DFC09E7Q37731654-B7F404EA-5F7E-48F3-9BE9-6DCE23FBA3C6Q38645392-A86EAEAE-5B65-4732-8C29-240CE5816E73Q38700897-7DE1B794-B8C1-4B3E-B19C-DDE13C15DF34Q38704324-D2531A8E-FFB4-4266-AABD-C3AB8A280F41Q38749030-D09BF82B-D929-42E2-B926-0B02BA8F79DFQ38848404-2F910E30-C45E-4238-8BC1-17158F0CB006Q38958552-1FA73176-B865-4C49-A24D-36EA72B78F09Q39020269-40969D9B-B8E5-45CD-8A68-13471C00705AQ39022941-AE6EB78C-6A4D-4713-A5B5-316BFFEAE5AAQ39024164-BD348A1B-14B7-4811-9B7D-BA3A6CD814B4Q39034031-C950AFB3-0617-4CC3-8887-20D28D75261BQ39067386-83C147EF-FEEB-48B7-A9C7-3B2E423DBFF4Q39210287-71E9AC51-AB18-46AA-B7F0-8BFCECFFD315Q39232340-D8542DF8-F657-431B-B533-188F8E829566Q39232954-D9D885E5-D4AD-4D57-BDD2-0318FFBC34FCQ39236837-2F16BC0D-BCB7-46EF-A63B-C34E659904ABQ39259089-E70D969B-826F-44AE-91D9-506C95266563Q39372488-C08D24A1-222C-4C7B-B434-D96811487CAFQ39398037-71A014CD-8D3A-4A5B-9D5B-EC7A72C3F31FQ39403862-8D8FB271-4E37-4330-99B5-99EFB6931ABFQ40444196-31D2C161-901A-4444-AB84-7B491FDDEB28
P2860
Antiangiogenic therapy in oncology: current status and future directions.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Antiangiogenic therapy in oncology: current status and future directions.
@en
type
label
Antiangiogenic therapy in oncology: current status and future directions.
@en
prefLabel
Antiangiogenic therapy in oncology: current status and future directions.
@en
P1433
P1476
Antiangiogenic therapy in oncology: current status and future directions.
@en
P2093
Lee M Ellis
Robert Kerbel
P304
P356
10.1016/S0140-6736(15)01088-0
P407
P577
2016-02-04T00:00:00Z